Comparison of Anti-Xa Activity After a Single Intravenous Bolus of Low-dose Enoxaparin in Patients With and Without End-stage Renal Disease

Author： Lin J-S   Wang W-J   Lin W-C   Wu X-M   Chao C-L  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.37, Iss.6, 2009-11, pp. : 1890-1896

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Elderly Medical Patients Treated with Prophylactic Dosages of Enoxaparin: Influence of Renal Function on Anti-Xa Activity Level

By Mahe Isabelle  

Drugs & Aging, Vol. 24, Iss. 1, 2007-01 ,pp. : 63-71

Adis International

Access to resources Recommend Favorite

Renal Function, Peak Anti‐Xa Levels and Enoxaparin Dosing

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 34, Iss. 1, 2004-03 ,pp. : 14-17

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K   Zussman B   Miller AK   Freed MI  

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Intravenous N -Acetylcysteine during Haemodialysis Reduces the Plasma Concentration of Homocysteine in Patients with End-Stage Renal Disease

By Thaha Mochammad  

Clinical Drug Investigation, Vol. 26, Iss. 4, 2006-01 ,pp. : 195-202

Adis International

Access to resources Recommend Favorite

"Sitagliptin dose adjustments are recommended for patients with moderate or severe RI [renal insufficiency] or ESRD [end-stage renal disease]"

By  

Inpharma, Vol. 1, Iss. 1601, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite